Case Studies

2025-06-20

AtaGenix Delivers Custom Rabbit Polyclonal Antibody Services for Haojie Hao’s Team at Wuhan Institute of Virology

AtaGenix Laboratories Co., Ltd. collaborated with the research team led by Haojie Hao at the Wuhan Institute of Virology to develop a custom mouse polyclonal antibody (pAb) against the Nipah virus (NiV) M protein, supporting a groundbreaking study published in Viruses (DOI: 10.3390/v17060831, IF: 3.8 Q2). The study revealed the critical role of N6-methyladenosine (m6A) modification in enhancing NiV replication and pathogenicity, particularly in the NiV-Malaysia strain. By designing specific antigens and delivering high-titer pAbs validated through Western blot assays in biosafety level 4 (BSL-4) conditions, AtaGenix enabled the team to confirm the M protein’s role in modulating host m6A machinery, advancing antiviral research.

2025-05-30

Professional Protein Expression and Antibody Customization Services to Support High-Impact Research on UGT Gene Family in Platycodon grandiflorus

A study identified 107 UGT genes in Platycodon grandiflorus, with PgUGT29 catalyzing the glycosylation of Platycodin D to D3. AtaGenix provides tailored protein expression and antibody customization, ensuring high-purity PgUGT29 (>95%) and specific anti-PgUGT29 antibodies for functional validation via HPLC and molecular docking, advancing saponin biosynthesis research.

2025-05-30

Professional Protein Expression and Antibody Customization Services for Grass Carp C5a-CP Adjuvant Research

Grass carp C5a-CP shows exceptional potential as a vaccine adjuvant, enhancing IgM⁺ B cell phagocytic activity and vaccine efficacy. We provide professional protein expression and antibody customization services, including IgM-CH expression and purification and anti-C5aR polyclonal antibody production, supporting functional validation with high purity and specificity to advance fish vaccine adjuvant research.

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

Stable Cell Line Development for Antibodies and Viral Proteins | AtaGenix Case Studies

Explore AtaGenix case studies on recombinant protein expression, including CHO stable cell lines achieving >3 g/L antibody yields and Bacillus subtilis systems for Protein A and B production. Data validated by SDS-PAGE, stability, purity, and affinity assays highlight AtaGenix’s expertise in high-quality protein expression solutions.

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Expression and Validation | AtaGenix Custom Antibody Development Services

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.

2024-11-05

Bispecific Antibody Development

This case study showcases the quality and functionality assessment of Dubody bispecific antibodies through QC, SEC-HPLC monomer purity, and ELISA titer analysis. The results confirm high purity and robust activity, supporting their application in therapeutic development.

2024-11-05

Protein A and Protein B Expression in Bacillus subtilis | High-Purity Recombinant Protein Solutions by AtaGenix

Discover how AtaGenix optimized Protein A secretion and Protein B intracellular expression in Bacillus subtilis. Case studies show high yields and >90% purity validated by SDS-PAGE, highlighting AtaGenix’s expertise in recombinant protein expression and quality control.

2024-11-05

HLA-I Expression and pMHC Tetramer Assembly in E. coli | AtaGenix

HLA-I protein and β2M were expressed and purified in E. coli, followed by refolding to form stable HLA/β2M/peptide complexes (pMHC). The addition of streptavidin (SA) enabled the formation of stable tetramers for downstream applications.

2024-11-05

Protein Expression & Case Studies | AtaGenix Recombinant Protein Solutions

This study demonstrates the optimization of E. coli expression systems for recombinant protein and antibody fragment production. Strategies included host strain selection, periplasmic expression for proper folding, and refolding inclusion bodies into active soluble proteins. Results showcase high-quality protein expression and QC validation.

2024-11-05

Antibody Gene Sequencing and Validation Case Study | AtaGenix Custom Antibody Development

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.